Colitis, Ulcerative study: Etrasimod
Official title A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
ClinicalTrials.gov ID: NCT07470879
What this study is testing
What is Etrasimod?
Etrasimod is an investigational once‑daily oral medicine being studied for the treatment of moderately to severely active ulcerative colitis in children.
Also referred to as APD334.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see if etrasimod is safe and works for kids with active ulcerative colitis and will measure how the drug behaves in the body.
- Who it's for
- Children aged 2 to 11 who have moderate or severe ulcerative colitis.
- What's involved
- Participants will receive etrasimod and have regular clinic visits and tests to monitor safety and disease activity.
- Time commitment
- The main study lasts 52 weeks, with the option to stay in a long‑term extension for up to 4 more years after enrollment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 11
You may be able to join if
- Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active Participants are permitted to be receiving a therapeutic dose of...
You likely can't join if
- Severe extensive colitis Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD...
The study team makes the final eligibility decision.
Where it is enrolling
- Indianapolis, Indiana, United States
- New York, New York, United States
- Westmead, New South Wales, Australia
- Brisbane, Queensland, Australia
- Clayton, Victoria, Australia
- Perth, Western Australia, Australia
- Winnipeg, Manitoba, Canada
- Québec, Quebec, Canada
- Bron, France
- Paris, France
- Münster, North Rhine-Westphalia, Germany
- Leipzig, Saxony, Germany
- Tübingen, Germany
- Wuppertal, Germany
- Ramat Gan, Central District, Israel
- Rehovot, Central District, Israel
- Tsrifin, Central District, Israel
- Jerusalem, Jerusalem, Israel
- Haifa, Northern District, Israel
- Bergamo, Lombardy, Italy
+ 13 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years to 11 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Indianapolis, Indiana, United States; New York, New York, United States; Westmead, New South Wales, Australia; Brisbane, Queensland, Australia; Clayton, Victoria, Australia; Perth, Western Australia, Australia and 27 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.